Cisplatin or Carboplatin
Sponsors
Fudan University, Robert Ferris, OncoMed Pharmaceuticals, Inc., NovoCure Ltd., Memorial Sloan Kettering Cancer Center
Conditions
Cervical CancerLung CancerMalignant Pleural MesotheliomaNon Small Cell Lung CancerNon-Small Cell Lung CancerNon-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid TumorNon-small Cell Lung CancerOtotoxicity
Sensorineural hearing loss
High frequency hearing loss
Toxic labyrinthitis
Phase 1
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy
TerminatedNCT01859741
Start: 2012-01-07End: 2017-05-08Updated: 2020-09-09
A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
Active, not recruitingNCT04162015
Start: 2019-11-12End: 2026-11-30Updated: 2025-09-12
A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies
RecruitingNCT06839105
Start: 2025-02-21End: 2028-04-30Target: 214Updated: 2025-05-31
Phase 2
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
NCT01192243
Start: 2009-12-31Target: 68Updated: 2010-09-03
ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
CompletedNCT01218048
Start: 2011-02-28End: 2017-02-14Updated: 2018-08-16
Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
CompletedNCT02397928
Start: 2015-02-28End: 2018-04-30Updated: 2018-09-25
A Study of AK104( an Anti-PD-1 and Anti-CTLA-4 Bispecific Antibody) in Recurrent or Metastatic Cervical Cancer
CompletedNCT04868708
Start: 2021-04-01End: 2024-02-28Updated: 2025-03-04
A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer
NCT04974827
Start: 2021-05-20End: 2023-05-20Target: 46Updated: 2021-08-10
A Study of Carilizumab Combined With Concurrent Chemoradiotherapy
NCT05151549
Start: 2021-12-01End: 2023-12-12Target: 46Updated: 2021-12-09
Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib
WithdrawnNCT05948462
Start: 2023-11-30End: 2025-09-30Updated: 2023-12-13
Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations
Not yet recruitingNCT06299371
Start: 2024-04-15End: 2029-04-15Target: 36Updated: 2024-03-07
A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer
Active, not recruitingNCT07005336
Start: 2025-01-09End: 2029-01-09Target: 150Updated: 2026-01-30
Phase 3
Phase 4
Related Papers
5 more papers not shown